

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI-77027
Title of the Manuscript:	Ginsenoside Re, produces multi-targeted potent antidiabetic effects via estrogen receptor signaling pathway in rat, an alternative multi-targeted therapeutic for type 2 diabetes
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal’s peer review policy states that **NO** manuscript should be rejected only on the basis of ‘**lack of Novelty**’, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	<div>1. Author should mention ethical clearance number</div> <div>2. Author Why not measure estrogen level ,,your findings mostly compared with estrogen signalling path way</div> <div>3. Why you used female Sprague dawley rats and clarify that</div> <div>4. Author used standard drug as rasglitazone that serve as insulin sensitizer</div> <div>Why not asses insulin sensitivity indices and add it</div> <div>5. Authur why not study estrogens receptor and mention weather extracellular memberan receptor and nuclear receptor in respect part.</div> <div>6. Previously reported that panaxadiols and penaxatriol has been toxic chemical substance to animals (SE CHEN ET AL 1980, Eur j drug metab pharmacokinetics) to avoid potential toxicity risk</div> <div>Author did you done toxicity study or Pharmacokinetic studies and should add data as tables it</div> <div>7. ANOVA replace with r ANOVA in statistical analysis of manuscript</div> <div>8. 3.5.Bcl2, Bax. and caspase and their mRNA expression.....</div> <div>Author must use up regulation and down regulation mRNA expression terms instead of either increased and decreased level of expression in term in your revised manuscript</div> <div>9. 3.7. RE Activates endothelial nitric oxide synthase (eNOS) through sex hormone receptor signalling.....</div> <div>Author mention name of sex hormone and its specific receptor name</div> <div>10. Authur should be described histopathological changes of pancreas in fig 5</div> <div>11.Author how multi-targeted therapeutic effect on multitargets via estrogen receptor and lined to DM2 clarify with scheme representation</div> <div>12. 4.3. Integrating of the multi-targeted potent antidiabetic effects of ginsenoside Re mediated by ER signalling pathway</div> <div>Author should reframe ER signalling because of different receptor mediated downstream molecules AMPK, GLUT4, GLP-1, PPAR-γ, SOD, Bcl-2, TNF-α, and NF-κB involved</div> <div>13, As I am reviewer suggested and advise to your new finding outcomes however Estrogen hormone therapy is not suitable for all sex and gender type 2 dm peoples because of Endocrine signal molecules and behavioral factors are involved in sex and gender inequalities and it could affect the therapeutic outcomes(Alexandra Kautzky-Willer, et al, Endocr Rev. 2016)</div> <div>Hence author need to more concentration and personalized diabetes care in the future and would thus promote more awareness in terms of sex- and gender-specific such risk factors.</div>	
<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments		

Review Form 1.6

PART 2:

	Reviewer’s comment	Author’s comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

Reviewer Details:

Name:	R. Saravanan
Department, University & Country	Annamalai University, India